Blood NfL levels are impacted by ALS clinical subtype, study finds
Elevated blood levels of neurofilament light chain (NfL), a biomarker of nerve cell damage, are linked to faster disease progression…
Articles by Margarida Maia, PhD
Europe’s CHMP recommends against masitinib authorization
An advisory committee of the European Medicines Agency (EMA) has recommended against granting conditional marketing authorization to masitinib as…
Fasudil safe, preserves motor neurons in early-stage ALS: Study
Treatment with fasudil (RT1968), which Raya Therapeutic is testing for amyotrophic lateral sclerosis (ALS), was safe and outperformed…
AB Science expects negative opinion on masitinib application in Europe
An advisory committee of the European Medicines Agency (EMA) is leaning against recommending the conditional approval of AB Science’s…
Clene expanding CNM-Au8 expanded access program in US
Clene Nanomedicine has nearly doubled the enrollment cap for a soon-to-launch expanded access program (EAP) to allow more patients…
Patient guide aims to increase, diversify clinical trial participation
The Les Turner ALS Foundation, in an effort to boost and diversify clinical trial participation, has written a step-by-step…
Extended treatment with NurOwn may offer additional benefits in ALS
People with amyotrophic lateral sclerosis (ALS) who continued treatment with NurOwn (debamestrocel) after completing a Phase 3 trial…
NeuroSense taps machine learning to optimize PrimeC Phase 3 testing
NeuroSense Therapeutics is collaborating with PhaseV for insights into how to better design the protocol for the planned…
Tambourine awards $5M to eight research projects into ALS
The Tambourine ALS Breakthrough Research Fund has committed more than $5 million in funding to eight research projects aiming to…
ALS women live longer than men despite faster functional decline
While women with amyotrophic lateral sclerosis (ALS) see a faster functional decline, men have shorter survival times, mostly due…